Global Non-Invasive Prenatal Testing Market Eyes Lucrative 16% CAGR to Reach $9 Billion by 2026

Increasing maternal age, cell-free DNA screening adoption, favorable reimbursement policies, and the increasing prevalence of genetic and congenital disorders are factors driving the global non-invasive prenatal testing market.
BRUSSELS - Oct. 19, 2023 - PRLog -- Non-invasive prenatal testing (NIPT), is a technique for evaluating if a mother's child will be born with certain genetic disorders. NIPT is a safe and effective method of screening for Down syndrome, Edwards syndrome, Patau syndrome, monosomy X, and Turner syndrome.

Shift towards Cell-Free DNA screening in the Non-Invasive Prenatal Testing Market

The discovery of cell-free DNA (cfDNA)-based NIPT has resulted in a fast shift in the paradigm of prenatal aneuploidy screening. It is a simple blood test that may be done while pregnant. NIPT appears to be more accurate than combined first-trimester screening (CFTS), with very high sensitivity (99.3%) and specificity (99.9%) for trisomy 21 (Down syndrome).

Advent of Advanced Technologies for NIPT Products Fuel the Non-Invasive Prenatal Testing Market

With the introduction of next-generation sequencing technology, fetal DNA fragments can now be sequenced and combined into a whole genetic map, allowing the fetal genome to be examined prenatally and non-invasively. The finding of cell-free fetal DNA in maternal plasma, as well as advances in molecular technology, have resulted in innovative screening approaches for fetal chromosomal aneuploidies.
  • In January 2022, QIAGEN entered into collaborations with Atila BioSystems to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN's dPCR franchise.
  • In June 2021, Illumina and Next-generation Genomic Thailand announced the launch of next-generation sequencing (NGS)-based VeriSeq NIPT Solution v2 in the country which helps to detect anomalies missed by targeted assays.
"Prenatal care is a dynamic and continuously evolving field. Development in new molecular technologies and the discovery of cell-free fetal DNA are fueling groundbreaking advancements to improve care for mother and child and to offer parents reproductive options." - Senior Director, Head of Research & Product Development, Sequencing & Array-based Company, United States

North America is the world's largest NIPT market.

North America is the largest market for NIPT, accounting for more than 45% of total sales, followed by Europe. Some of the main factors driving the North America market include the increasing frequency of genetic abnormalities in infants related with increasing mother age, greater adoption, and the presence of top firms focusing on fetal and neonatal care in this area.

Competitive Landscape Analysis: Non-Invasive Prenatal Testing Market

Some of the prominent players operating in the global non-invasive prenatal testing market are Agilent Technologies, BGI Genomics, Cradle Genomics, Berry Genomics, Sequenom, Roche (Ariosa Diagnostics), among others.

Explore Detailed Insights on Global Non-Invasive Prenatal Testing (NIPT) Market @

Ruta Halde
Source: » Follow
Posted By:*** Email Verified
Location:Brussels - Brussels - Belgium
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Medi-tech Insights PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share